SCHEMBL30205997

SCHEMBL30205997

COc1nc(Nc2ccc(N3CCOCC3)cc2)c(C(N)=O)nc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EML4 Q9HC35 5/20 0.54
▸ ALK Q9UM73 5/20 0.54
▸ MAPK8 P45983 2/20 0.49
▸ MAPK9 P45984 2/20 0.49
▸ MAPK10 P53779 2/20 0.49
▸ JAK3 P52333 2/20 0.49
▸ LCK P06239 1/20 0.49
▸ RET P07949 4/20 0.49
▸ ROS1 P08922 4/20 0.49
▸ FLT3 P36888 4/20 0.49
▸ CSF1R P07333 2/20 0.47
▸ SYK P43405 3/20 0.47
▸ STAT6 P42226 2/20 0.46
▸ PTK2 Q05397 1/20 0.46
▸ JAK2 O60674 1/20 0.45
▸ JAK1 P23458 1/20 0.45
▸ TYK2 P29597 1/20 0.45
▸ EGFR P00533 1/20 0.45
▸ AURKA O14965 1/20 0.44
▸ CDK4 P11802 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29173538 1.00 EML4 (0.54) EML4ALKMAPK8MAPK9MAPK10
SCHEMBL29173638 0.91 PTK2 (0.46) EML4ALKMAPK8MAPK9MAPK10
SCHEMBL30206096 0.91 PTK2 (0.46) EML4ALKMAPK8MAPK9MAPK10
SCHEMBL29173401 0.89 EML4 (0.56) EML4ALKMAPK8MAPK9MAPK10
SCHEMBL30206368 0.89 EML4 (0.56) EML4ALKMAPK8MAPK9MAPK10
SCHEMBL30206068 0.85 EML4 (0.58) EML4ALKMAPK8MAPK9MAPK10
SCHEMBL29173494 0.85 EML4 (0.58) EML4ALKMAPK8MAPK9MAPK10
SCHEMBL10126777 0.82 EML4 (0.67) EML4ALKMAPK8MAPK9MAPK10
SCHEMBL29173515 0.80 PIM1 (0.48) EML4ALKJAK3SYKSTAT6
SCHEMBL30206208 0.80 PIM1 (0.48) EML4ALKJAK3SYKSTAT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed
Send feedback